ライフサイエンスコーパス: CMR

1 CMR assessment of RV function may be important in the ri

2 CMR can also provide data on certain functional and stru

3 CMR diagnostic criterion of LVNC (noncompacted/compacted

4 CMR evidenced progressive RV hypertrophy and dysfunction

5 CMR findings suggested the diagnosis of EGPA by demonstr

6 CMR identified a likely pathogenesis for sudden cardiac

7 CMR is a non-invasive modality that can help identify po

8 CMR is a useful noninvasive tool, which may be incorpora

9 CMR may be able to identify appropriate patients for ear

10 CMR parameters indicating myocardial inflammation were e

11 CMR predictors of CEs were LV dilation and LGE.

12 CMR protocol allowed for the determination of cardiac fu

13 CMR provides additional prognostic stratification as com

14 CMR quantification accurately identified patients who pr

15 CMR quantification of mitral regurgitation was associate

16 CMR showed higher left ventricle end-diastolic volume (m

17 CMR T1 mapping is a quantitative imaging technique allow

18 CMR tissue characterization provides effective risk stra

19 CMR was associated with a greater 1-y progression-free s

20 CMR was calculated.

21 CMR was performed in 342 patients (54.8%).

22 CMR-derived end-diastolic volume index showed a weaker a

23 CMR-measured infarct size declined progressively after r

24 CMR-measured myocardial salvage, and the extent of intra

25 CMRs and natural logarithm of SMRs were pooled by the me

26 s group, 0.21 (95% CI, 0.12-0.34, P < .001); CMR group vs the MPS group, 1.27 (95% CI, 0.79-2.03, P =

27 ransformation to myelofibrosis occurred in 1 CMR patient, presumably because of the emergence of a di

28 6 male patients with DMD or BMD undergoing 2 CMR studies with a 2-year interval for ventricular funct

29 tion patients underwent acute and 6-month 3T CMR, including cine, T2-weighted (T2W) imaging, native s

30 ay 7 CMR) and highest long-term LVEF (day 45 CMR).

31 (LVEF) (48.3% vs. 43.9%; p = 0.019) on day 5 CMR.

32 guidelines group, 1.37 [95% CI, 0.52-3.57]; CMR group vs MPS group, 0.95 [95% CI, 0.46-1.95]).

33 eperfusion) had the smallest infarcts (day 7 CMR) and highest long-term LVEF (day 45 CMR).

34 Patients attaining a CMR had a 96% overall response rate by IWG criteria, wit

35 Of the 8 patients not attaining a CMR, 6 responded to BR but none achieved a complete resp

36 (18)F-FDG PET, negative scans, indicating a CMR, were predictive of improved 1-y survival, duration

37 MACE associated with presence of a CMR diagnosis, extent of late gadolinium enhancement, an

38 s model of survival outcome indicated that a CMR was the only significant predictor of PFS and CSS (P

39 ous coronary intervention (PPCI) underwent a CMR at 4 +/- 2 days and 5 +/- 2 months.

40 were prospectively recruited and underwent a CMR at 4 +/- 2 days.

41 of this study was to develop and validate a CMR-based risk score for ST-segment-elevation myocardial

42 jects had MACE; risk doubled in those with a CMR diagnosis and some CMR parameters-late gadolinium en

43 Patients with Ph(+) ALL who achieve CMR at 3 months have superior survival compared with tho

44 At acute CMR 32% of segments were dysfunctional, and at follow-up

45 TEI on the acute CMR scan had an area-under-the-curve of 0.87 (95% confid

46 ients follows a bimodal pattern that affects CMR estimates of MaR.

47 Although CMR is considered the standard of reference for measurin

48 At multivariable analysis, CMR-LVEF </=35% (hazard ratio=2.18 [1.3-3.8]) and the pr

49 The correlation between the 2DE and CMR tools (r=0.449 p<0.004), however, was only moderate.

50 While the correlation between 2DE and CMR tools was satisfactory for ESV, EDV, and CO values,

51 0.702 p<0.001), and between the MR-Argus and CMR tools (r=0.746 p<0.001).

52 e is a relationship between the MR-Argus and CMR tools software programs which are used in post-proce

53 esults from the two MR methods (MR-Argus and CMR tools) and the results from both the MDCT and the 2D

54 gh the widespread adoption of cardiac CT and CMR will require further evidence of clinical efficacy a

55 tion of CEs, compared with clinical data and CMR functional parameters in all 3 models.

56 r exclusion of coronary artery disease), and CMR imaging on 1.5- and 3-T scanners.

57 .1 years) who underwent echocardiography and CMR imaging within 6 months (median, 41 days; interquart

58 LVWT difference between echocardiography and CMR was 0.5 mm (95% confidence interval, -6.9, 7.8) with

59 patients as measured by echocardiography and CMR, respectively.

60 ngthened: catch bonds by constant forces and CMR by cyclic forces.

61 or EF values were found between the MDCT and CMR tools (r=0.702 p<0.001), and between the MR-Argus an

62 correlation coefficient between the MDCT and CMR tools is close to the correlation coefficient betwee

63 es had both serum NT-proBNP measurements and CMR with T1 mapping of indices of fibrosis at 1.5 T.

64 All patients underwent TTE and CMR, and left ventricle end-diastolic volume, left ventr

65 usted odds ratio of unnecessary angiography: CMR group vs NICE guidelines group, 0.21 (95% CI, 0.12-0

66 At CMR (n = 792), the myocardial salvage index was signific

67 healthy pigs were euthanized after baseline CMR as reference.

68 ular systolic function derived from baseline CMR and resting oxygen saturation are associated with mo

69 or severe mitral regurgitation had baseline CMR scans and were followed up for up to 8 years (mean,

70 ed ambient PM2.5 exposure in the year before CMR; individually weighted estimates accounted for indoo

71 statistically significant difference between CMR and MPS strategies.

72 We identify an inverse relationship between CMR and sequence length in an in silico system with a tw

73 lso identify an inverse relationship between CMR and the number of genes, confirming that, for a simi

74 r volumes and mass, the relationship between CMR findings of right ventricular (RV) function and outc

75 BOLD-CMR showed promise as a reliable tool for assessing perf

76 BOLD-CMR was used to assess changes in perfusion following re

77 This study sought to develop BOLD-CMR as an objective, reliable clinical tool for measurin

78 sies (n = 28), obtained at the level of BOLD-CMR measurement and from healthy proximal muscle of pati

79 dent cardiovascular magnetic resonance (BOLD-CMR) to assess perfusion in the lower limb has been hamp

80 ducted in a high-volume institution for both CMR and SPECT).

81 Infarct size was assessed by CMR in 1,889 patients (71.8%) and by SPECT in 743 patien

82 ng the prognostic value of AR as assessed by CMR post-TAVR.

83 Diffuse myocardial fibrosis, assessed by CMR-derived T1 mapping, independently predicts invasivel

84 sional echocardiography and in short axis by CMR.

85 Myocardial scar detected by CMR imaging.

86 nical myocardial inflammation as detected by CMR may be a potential precursor of the increased cardio

87 Shunt flow by CMR strongly correlated with PH severity, left ventricul

88 LV ejection fraction by CMR was 51.0 +/- 10.9% in the metoprolol group and 51.6

89 ents with suspected angina, investigation by CMR resulted in a lower probability of unnecessary angio

90 rct size (percent of left ventricle [LV]) by CMR did not differ between the metoprolol (15.3 +/- 11.0

91 Infarct size, measured by CMR or technetium-99m sestamibi SPECT within 1 month aft

92 n 7 patients (7.2%), reported measurement by CMR was inaccurate because of interpretation error.

93 in patients with ST-segment-elevation MI by CMR and assessed its implications for myocardium-at-risk

94 Therefore, the optimal cut-off by CMR during the acute phase of an MI to predict viability

95 Extracellular volume by CMR in different myocardial regions was studied in 20 an

96 ed monthly with right heart catheterization, CMR, and computed tomography during 4 months, followed b

97 In total, 94 clinical CMR examinations were performed: patients with ST-segmen

98 Comprehensive CMR imaging was performed in 1 study.

99 Comprehensive CMR revealed a high burden of cardiovascular disease in

100 refractory or advanced disease demonstrated CMR in more than half.

101 In swine, a DT-CMR index of sheetlet reorientation (E2A) changed substa

102 fusion tensor cardiac magnetic resonance (DT-CMR) may enable noninvasive interrogation of in vivo car

103 This study sought to validate in vivo DT-CMR measures of cardiac microstructure against histology

104 In vivo DT-CMR was acquired throughout the cardiac cycle in healthy

105 In vivo DT-CMR was performed in 19 control subjects, 19 DCM, and 13

106 hy swine, followed by in situ and ex vivo DT-CMR, then validated against histology.

107 dynamics can be characterized by in vivo DT-CMR.

108 Contrast-free DW-CMR is an alternative sequence to ECV for the evaluation

109 sis quantified by extracellular volume (ECV) CMR measures.

110 er study on Acute MYocarditis) and evaluated CMR results from 386 patients (299 male; mean age 35 +/-

111 Here, we used multi-event CMR methods to investigate whether the number of helpers

112 tory effect and agrees with the experimental CMR effect of integrin alpha5beta1-fibronectin interacti

113 After the final CMR, hearts were excised and processed for water content

114 internal states and hence are inadequate for CMR.

115 Here we propose a three-state model for CMR where both loading and unloading regulate the transi

116 ith preserved systolic function referred for CMR were eligible.

117 udies have demonstrated a potential role for CMR in the diagnostic evaluation of patients with crypto

118 atomic location of LGE signal intensity from CMR.

119 ture tracking-cardiac magnetic resonance (FT-CMR) is emerging as a novel, simple and robust method to

120 In all groups, CMR-measured edema was barely detectable at 24 hours pos

121 decreased contractility at 120 min- and 24 h-CMR accompanied by transient alterations in contractile

122 ted short-tau triple inversion-recovery (ie, CMR-MaR) were evaluated at all time points.

123 essed by cardiac magnetic resonance imaging (CMR) at 30 days.

124 Cardiac magnetic resonance imaging (CMR) provides both cardiac anatomy and tissue characteri

125 -21.5%), cardiac magnetic resonance imaging (CMR, as part of an ongoing study), high-sensitivity trop

126 To implement CMR imaging in noninvasive risk stratification to predic

127 The decrease in CMR with population size previously observed is maintain

128 There was no trend in CMRs, all-cause, and gender-specific SMRs.

129 o perform full cardiac imaging that includes CMR even in asymptomatic patients with suspected EGPA, s

130 le analysis, AS LGE was the best independent CMR predictor of the combined endpoint (odds ratio: 2.73

131 ocations were transferred onto an individual CMR-derived 3-dimensional shell.

132 l requires invasive investigations and lacks CMR imaging to identify high-risk patients.

133 co system with a two-peak fitness landscape; CMR decreases to no more than five orders of magnitude a

134 LGE CMR of both atria was performed, and NEEES-based analysi

135 left atria data sets, including 86 axial LGE CMR planes per atrium.

136 conductivity and colossal magnetoresistance (CMR) in strongly-correlated materials.

137 pacts diagnosis and sudden death management, CMR should be considered as part of routine evaluation o

138 measured by phase-contrast velocity mapping CMR at a median of 40 days post-TAVR, and using Doppler

139 d from personalized heart models by matching CMR-imaged LV dynamics.

140 Moreover, CMR is associated with good survival outcome.

141 Cardiac MRI (CMR) has been used for cardiac disorders, but its use in

142 n (11)C-acetate PET/CT scan and cardiac MRI (CMR).

143 hereas 32 displayed incomplete response (non-CMR): 15 patients with partial response and 17 with dise

144 A normal CMR study corresponded to low annual MACE and death rate

145 Objective: To establish the ability of CMR and SPECT to predict major adverse cardiovascular ev

146 At 3 months, achievement of CMR vs response less than CMR was associated with longer

147 ) in MS, and estimated the rate of change of CMR and SMR over the past 50 years.

148 We evaluated the impact of CMR on outcomes among 85 patients with Ph(+) ALL who rec

149 ach integrates the prognostic information of CMR imaging into a simple risk score that showed increme

150 This study assessed the performance of CMR imaging, including T1 and T2 mapping, compared with

151 was to evaluate the prognostic relevance of CMR findings in patients with LVNC.

152 ne, raising questions about the relevance of CMR in ET patients.

153 es or to guided care based on the results of CMR or MPS testing.

154 This study sought to evaluate the role of CMR and LGE in the prognosis of AM with preserved LVEF.

155 This further supports the role of CMR as an alternative to SPECT for the diagnosis and man

156 It also examined the potential role of CMR field strength by comparing 1.5-T versus 3.0-T imagi

157 ities, and we sought to evaluate the role of CMR in determining sudden cardiac arrest pathogenesis an

158 ma highlight the need for standardization of CMR timing to retrospectively delineate MaR and quantify

159 The literature on the use of CMR in the diagnostic evaluation of ischaemic stroke is

160 ative studies and case series) on the use of CMR in the diagnostic evaluation of patients with ischae

161 e studies are needed to compare the value of CMR as compared to transthoracic and transesophageal ech

162 A model based on CMR-LVEF </=35% or CMR-LVEF </=35% plus late gadolinium

163 reserved and MF was present as determined on CMR, ACE inhibitor therapy was associated with significa

164 h repaired TOF, biventricular dysfunction on CMR imaging was associated with major adverse clinical o

165 surrogate for myocardial diffuse fibrosis on CMR imaging, and higher ECV values are associated with a

166 ly in the absence of ventricular fibrosis on CMR.

167 Abnormal findings on CMR (hazard ratio, 2.77 [95% CI, 1.85 to 4.16]; P < 0.00

168 ility was associated with edema formation on CMR and increases in inflammation and wound healing prot

169 Patients with MF noted on CMR had a higher probability of cardiovascular events (e

170 Only CMR remained a significant predictor after adjustment fo

171 By multivariate analysis, only CMR at 3 months was prognostic for OS (hazard ratio, 0.4

172 the experimental model by showing that only CMR-MaR values for day 4 and day 7 postreperfusion, coin

173 A model based on CMR-LVEF </=35% or CMR-LVEF </=35% plus late gadolinium enhancement detecti

174 Therefore, ASL perfusion CMR may be an alternative method for quantifying the AAR

175 gated arterial spin labeling (ASL) perfusion CMR as a novel approach to quantify the AAR following AM

176 al infarction (n=21) who underwent perfusion CMR before invasive angiography were 92% and 93%, respec

177 Pooled CMR was 9.78/1000 person-years (95% CI 6.81 to 14.02).

178 Recent studies have reported immediate post-CMR DNA double-strand breaks in T lymphocytes.

179 RV function, measured on preprocedural CMR, is an independent predictor of mortality after tran

180 The critical mutation rate (CMR) determines the shift between survival-of-the-fittes

181 We compared crude mortality rates (CMRs) for all-cause and drug-related overdose mortality,

182 c and gender-specific crude mortality rates (CMRs), and standardised mortality ratios (SMRs) in MS, a

183 fer was defined as the cord-to-mother ratio (CMR) of antibody levels.

184 5% in the MPS group (adjusted hazard ratios: CMR group vs NICE guidelines group, 1.37 [95% CI, 0.52-3

185 eighted short-tau triple inversion-recovery (CMR-MaR) varied with the timing of the CMR examination.

186 Maternal HIV was associated with reduced CMR of MSP1 IgG1 (P = .022) and IgG3 (P = .023), lysate

187 s is termed cyclic mechanical reinforcement (CMR).

188 patients (18 AMR, 8 cell-mediated rejection [CMR], 38 no rejection in desensitized [DES] and non-DES

189 rimary endpoint was change in LVEF on repeat CMR at 6 months.

190 cardiography and cardiac magnetic resonance (CMR) and document causes of discrepancy.

191 ognostic role of cardiac magnetic resonance (CMR) and late gadolinium enhancement (LGE) has not been

192 comparing cardiovascular magnetic resonance (CMR) and single-photon emission computed tomography (SPE

193 s followed up by cardiac magnetic resonance (CMR) and tissue samples were analyzed by multiplexed qua

194 a comprehensive cardiac magnetic resonance (CMR) approach.

195 Cardiovascular magnetic resonance (CMR) can accurately quantify mitral regurgitation, and w

196 Cardiovascular magnetic resonance (CMR) can detect morphological, functional, or tissue abn

197 Cardiovascular magnetic resonance (CMR) can provide important structural information in pat

198 015, at a cardiovascular magnetic resonance (CMR) center serving an integrated health system.

199 eformation using cardiac magnetic resonance (CMR) cine imaging.

200 Cardiac magnetic resonance (CMR) demonstrated great potential for the prediction of

201 cal outcomes and cardiac magnetic resonance (CMR) findings in STEMI patients with and without diabete

202 of TEI by cardiovascular magnetic resonance (CMR) for defining viability during the acute phase of an

203 erosis performed cardiac magnetic resonance (CMR) imaging among participants 45-84 years old without

204 ent (LGE) cardiovascular magnetic resonance (CMR) imaging can be used to evaluate characteristics of

205 Cardiovascular magnetic resonance (CMR) imaging is recommended to quantify right ventricula

206 Cardiac magnetic resonance (CMR) imaging is used to evaluate the myocardium, valves,

207 zation by either cardiac magnetic resonance (CMR) imaging or technetium-99m sestamibi single-photon e

208 Cardiac magnetic resonance (CMR) is a component of the revised Task Force Criteria (

209 Cardiac magnetic resonance (CMR) is increasingly used for the diagnosis and manageme

210 Cardiovascular magnetic resonance (CMR) is purported as a more accurate means of quantifyin

211 Cardiac magnetic resonance (CMR) is useful for the diagnosis of left ventricular non

212 of comprehensive cardiac magnetic resonance (CMR) mapping versus endomyocardial biopsy (EMB) has not

213 tionship between cardiac magnetic resonance (CMR) measures of fibrosis and NT-proBNP levels in the ME

214 on (MI) heart by cardiac magnetic resonance (CMR) need to be standardized to take account of dynamic

215 ography (CT) and cardiac magnetic resonance (CMR) now allow detailed imaging of each of these differe

216 ostic benefit of cardiac magnetic resonance (CMR) over transthoracic echocardiography (TTE) in ischem

217 le tracking, and cardiac magnetic resonance (CMR) T1 mapping were performed; all of the rabbits were

218 tients underwent cardiac magnetic resonance (CMR) to assess LVEF and late gadolinium enhancement, ind

219 -weighted cardiovascular magnetic resonance (CMR) using a 3-slice approach has been shown to accurate

220 -enhanced cardiovascular magnetic resonance (CMR) was performed following PPCI (median day 3) and str

221 Cardiac magnetic resonance (CMR) was performed in the acute and chronic phases in bo

222 , as measured by cardiac magnetic resonance (CMR), are not well established in Chinese populations.

223 Cardiac magnetic resonance (CMR), with late gadolinium enhancement (LGE) and T1 mapp

224 Serial cardiac magnetic resonance (CMR)-based tissue characterization was done in all pigs

225 Cardiac magnetic resonance (CMR)-derived T1 mapping can noninvasively quantify diffu

226 nary shunt using cardiac magnetic resonance (CMR).

227 romocytoma using cardiac magnetic resonance (CMR).

228 tified on cardiovascular magnetic resonance (CMR).

229 ct of achieving complete molecular response (CMR) in Philadelphia chromosome-positive (Ph(+)) acute l

230 ch the stage of complete molecular response (CMR), defined as the point when BCR-ABL transcripts beco

231 8)F-FDG uptake (complete metabolic response [CMR]) in 55 patients whereas 32 displayed incomplete res

232 Complete metabolic responses (CMR) were observed in 24 (75%) patients after 6 cycles o

233 ; there were 2 complete molecular responses (CMR) and 1 partial molecular response in CALR-positive r

234 nute ischemia/reperfusion followed by serial CMR examinations at 120 minutes and 1, 4, and 7 days aft

235 A single CMR acquisition of native T1 mapping could potentially r

236 ubled in those with a CMR diagnosis and some CMR parameters-late gadolinium enhancement, left ventric

237 RC study indicates that compared with SPECT, CMR is a stronger predictor of risk for MACEs, independe

238 minatory ability than the reference-standard CMR-derived ventricular volumes.

239 med following PPCI (median day 3) and stress CMR at 9 months.

240 Stress-CMR strategy was associated with a significant reduction

241 The mean follow-up for cTCA and stress-CMR groups was similar (773.6+/-345 versus 752.8+/-291 d

242 Compared with cTCA, stress-CMR is more cost-effective in symptomatic revascularized

243 anatomic (cTCA) versus a functional (stress-CMR) strategy in symptomatic patients with previous myoc

244 an age 68.2+/-9.7 years, male 255) or stress-CMR (n=300, mean age 67.6+/-9.7 years, male 263) were en

245 nd stress cardiac magnetic resonance (stress-CMR) are suitable tools for diagnosing obstructive coron

246 Finally, patients undergoing stress-CMR showed a lower rate of major adverse cardiac events

247 Compared with stress-CMR, cTCA was associated with a higher rate of subsequen

248 This first systematic CMR study characterizing the cardiac phenotype in pheoch

249 ading to an underestimation of the AAR by T2-CMR.

250 ighted cardiovascular magnetic resonance (T2-CMR) of myocardial edema can quantify the area-at-risk (

251 A total of 190 patients underwent 1.5 Tesla CMR before transcatheter aortic valve implantation.

252 hs, achievement of CMR vs response less than CMR was associated with longer median OS (127 vs 38 mont

253 The CMR protocol included current standard Lake Louise crite

254 The CMR tools LV tutorials method is accepted as the gold st

255 The CMR variables were combined with the noninvasive compone

256 the plant Arabidopsis thaliana (25,000), the CMR is close to its known wild-type mutation rate; mutat

257 os in multivariable regression analysis, the CMR risk score was created by attributing 1 point for LV

258 We confirm the CMR reduces exponentially at low population sizes, irres

259 95% CI, 7.3%-12.8%; 47/481 patients) for the CMR group, and 8.7% (95% CI, 6.4%-11.6%; 42/481 patients

260 up (42.5% [95% CI, 36.2%-49.0%])], 85 in the CMR group (17.7% [95% CI, 14.4%-21.4%]); and 78 in the M

261 ts in the NICE guidelines group, 2.5% in the CMR group, and 2.5% in the MPS group (adjusted hazard ra

262 the NICE guidelines group, 36 (7.5%) in the CMR group, and 34 (7.1%) in the MPS group; adjusted odds

263 very (CMR-MaR) varied with the timing of the CMR examination.

264 Inclusion of the CMR score in addition to a model of clinical risk factor

265 d to be within one order of magnitude of the CMR.

266 was significantly higher in the AMR than the CMR (P < 0.0001) and no rejection control groups (P < 0.

267 ults from both the MDCT and the 2DE with the CMR tools results.

268 obstruction varied dramatically according to CMR timing, ischemia duration, and cardioprotective stra

269 y accuracy in the controls was comparable to CMR.

270 rt with suspected myocarditis with regard to CMR findings.

271 ocardiography in general measured similar to CMR, discordance because of limitations in echocardiogra

272 (n=28) and control subjects (n=22) underwent CMR.

273 iography and echocardiography, all underwent CMR and, when indicated, electrophysiology studies.

274 history of cardiovascular disease, underwent CMR at 1.5 T including cine, DENSE, and late gadolinium

275 chocardiographic diagnosis of LVNC underwent CMR at 5 referral centers.

276 atients with suspected myocarditis underwent CMR including late gadolinium enhancement (LGE) paramete

277 Participants underwent CMR at baseline and after 6-months of standard care.

278 Of 628 who underwent CMR, SPECT, and the reference standard test of X-ray ang

279 egments were dysfunctional, and at follow-up CMR 19% were dysfunctional.

280 The authors used CMR with extracellular volume fraction (ECV) measurement

281 We used CMR to consider changes in LV mass, myocardial strain an

282 nsive control subjects (HTN) (n = 14), using CMR (1.5-T) cine, strain imaging by myocardial tagging,

283 In patients with LVNC evaluated by using CMR, the degree of LV trabeculation seems to have no pro

284 sis that can be detected and monitored using CMR.

285 ed significant incremental predictive value; CMR performed a median of 40 days post-TAVR had a greate

286 e for imaging the coronary arteries, whereas CMR offers detailed assessments of myocardial perfusion,

287 ies are required to definitely state whether CMR can be used safely, our findings already call for ca

288 om a prospective nationwide registry in whom CMR was performed.

289 Quantifying AR with CMR may identify patients with AR who could benefit from

290 t to evaluate the effect of AR assessed with CMR on clinical outcomes post-TAVR.

291 went a standardized baseline assessment with CMR, blood test, echocardiography, and 6-minute walk tes

292 nificantly increased among AMR compared with CMR and/or control patients.

293 PET measurements were compared with CMR.

294 The 2-y CSS was 100% for patients with CMR and 59% (95% CI, 42-84) for those without CMR (P < 0

295 xamine the association of log NT-proBNP with CMR T1 mapping indices.

296 rvival of 91.5%, compared with 12.5% without CMR; a longer median duration of response of 20.6 mo, co

297 MR and 59% (95% CI, 42-84) for those without CMR (P < 0.0001).

298 Worse CMR-quantified AR was associated with increased mortalit

299 s MF progression from baseline to the 2-year CMR study.

300 bjects (65% men; mean age 48 [18-80] years), CMR contributed to the diagnosis in 80 (49%) and was dec